Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.

• Revenue in USD (TTM)103.00k
• Net income in USD-12.54m
• Incorporated2012
• Employees12.00

• Location
  Organovo Holdings IncSuite 100, 11555 Sorrento Valley RoadSAN DIEGO 92121United StatesUSA
• Phone+1 (858) 224-1000
• Fax+1 (302) 636-5454
• Websitehttps://organovo.com/